Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04730505 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04730505 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 2 participants.
The verdict
NCT04730505, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
NDS-MM-004 is a multi-center, randomized, pilot trial to evaluate the MyHOPE for multiple myeloma (MM) Platform in patients with MM. The MyHOPE for MM Platform is a validated investigational device manufactured by Amalgam Rx, Inc. and designed to provide patients with a comprehensive set of tools and resources to support the patient throughout their overall experience with MM.
Interventions
- DEVICE MyHOPE™ for Multiple Myeloma
- DEVICE MyHope HCP Portal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-02-04 |
| Est. Completion | 2021-06-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04730505
The ClinicalTrials.gov registry entry for NCT04730505 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MyHOPE™ for Multiple Myeloma is the first listed.
NCT04730505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04730505 about?
NCT04730505 is a clinical study titled "A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM". NDS-MM-004 is a multi-center, randomized, pilot trial to evaluate the MyHOPE for multiple myeloma (MM) Platform in patients with MM. The MyHOPE for MM Platform is a validated investigational device manufactured by Amalgam Rx, Inc. and designed to provide patients with a comprehensive set of tools an...
What is the current status of trial NCT04730505?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2021-02-04. Estimated completion is 2021-06-21.
What interventions are being tested in trial NCT04730505?
The interventions under investigation include: MyHOPE™ for Multiple Myeloma (DEVICE), MyHope HCP Portal (DEVICE).
Who is sponsoring clinical trial NCT04730505?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.